BTB01303 is a glutamate release inhibitor that targets the high levels of glutamate released by cancer cells, which disrupts normal bone turnover and can lead to cancer-induced bone pain. BTB01303 has the potential to improve cancer-induced bone pain [1].
Molekulargewicht:
324.16
CAS Nummer:
[652129-89-0]
Formel:
C15H11Cl2NO3
Target-Kategorie:
Others|||GluR
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten